In general, progestins have been characterized to exert their genomic effects in breast cancer cells and other tissues through binding to the intracellular progesterone receptor (PR), a ligand-dependent transcription factor that is dimerized and translocated to the nucleus upon activation. Here, PGR is linked to breast carcinoma.